Actively Recruiting
Association Between the Level of EV-TF and the Occurence of Pulmonary Embolism in Patients With ARDS
Led by Assistance Publique Hopitaux De Marseille · Updated on 2026-02-04
170
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this study, 120 patients with Acute Respiratory Distress Syndrome (ARDS) will be included on a two years-period in an intensive care unit (Assistance Publique des Hôpitaux de Marseille, France). Those patients will benefit from a blood test at inclusion in order to measure several coagulation biomarkers, including EV-TF. Subsequently, these patients will be treated according to the usual practices of the department, following recommendations. Patients who received an injected CT scan between Day 5 and Day 28 will be divided into two groups based on the presence or absence of a pulmonary embolism on imaging. The measured values of EV-TF levels and other studied biomarkers will be compared between these two groups in order to detect a possible association between them and the diagnosis of pulmonary embolism. It should be noted that patients receiving an injected CT-scan between Day 5 and Day 7 will be included in the main analysis while those receiving it between Day 8 and Day 28 will be included in the secondary analysis. Others will be excluded from any analysis. At the same time, several collections of clinical data will be carried out: on Day 1, Day 7, Day 28, and on the day of the CT scan if it is performed at another time.
CONDITIONS
Official Title
Association Between the Level of EV-TF and the Occurence of Pulmonary Embolism in Patients With ARDS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient 18 years of age or older
- Patient who has given his/her non-opposition to participate in this study, or alternatively, patient for whom a relative has given his/her non-opposition to participate in this study
- Patient admitted to intensive care for less than 24 hours
- Patient with ARDS according to the Berlin criteria, including:
- Hypoxemia with PaO2/FiO2 ratio 64 300 on mechanical ventilation under PEEP 65 5 cmH2O
- Bilateral alveolar-interstitial opacities on chest imaging (chest X-ray or CT)
- Exclusion of a cardiogenic cause on echocardiography
- Acute or subacute onset within 7 days based on the clinical-radiological profile
You will not qualify if you...
- Positive SARS-CoV-2 PCR in a pharyngeal or respiratory sample prior to admission to the intensive care unit
- Patient with a pathology affecting the coagulation process or endothelial function (hemophilia, von Willebrand disease, etc.)
- Patient receiving curative anticoagulant treatment before admission to intensive care
- Patient undergoing extracorporeal veno-venous respiratory assistance (ECMO-VV) before admission
- Patient undergoing extra-renal purification with systemic anticoagulation with heparin before admission
- Minor patients, adult patients under tutorship or guardianship, patients deprived of liberty, pregnant or nursing women
- Moribund patients with life expectancy less than 24 hours according to the investigating physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Service Médecine intensive et réanimation
Marseille, France, 13015
Actively Recruiting
Research Team
G
Giovanni Bousquet, MD
CONTACT
C
Christophe Guervilly, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here